Markets, explained.

Three Supply Shocks Converging: Hormuz Deadlock, China Tech Retaliation, and Ukraine Black Sea Strikes

Three geopolitical chokepoints are tightening at once — Hormuz remains blocked with traffic down 90%, US-China trade war escalates with polysilicon tariffs and counter-sanctions, and Ukraine strikes Russia's Black Sea grain hub. Energy stocks and gold rose while bonds and the dollar eased — a stagflationary supply-shock footprint, not classic risk-off.

Record-High Hangover: Broadcom's Crack Pulls Tech Down While Energy Quietly Takes the Baton

Equity Supply Meets a Calm VIX: Lockups, Secondaries, and the Order Protection Rule

SpaceX's first lockup freed 912 million shares and the stock rallied 35% — but 12.9 billion more unlock by mid-2027. Secondaries cluster, the SEC proposes rescinding the Order Protection Rule, and US equity supply turns positive for the first time in 23 years. The VIX is calm; the plumbing is not.

Hormuz at a Standstill: Oil's Weekly Surge Meets a Faltering US Consumer

Oil posted its strongest weekly gain in months as the US vowed an 'indefinite' blockade of Iran, with Brent closing at $88.52. On the same day, July retail sales fell 0.6% and consumer sentiment dropped to 51 — a stagflationary signal that knocked the S&P 500 from its Thursday record.

Consumer Cracks Pull Indexes Off Record Highs as Small Caps Buck the Tape

The S&P 500 notched a record high Thursday on soft PPI, but Friday's retail-sales plunge and consumer-sentiment drop exposed cracks beneath the surface. Energy and small caps outperformed; tech and healthcare lagged. Iran tensions kept a bid under oil.

Lockups, Biotech, and Defense: The 2026 IPO Market's Mid-August Stress Test

SpaceX's record lockup expiry passed without a selloff, biotech IPOs extended their winning streak, and a $528M defense-tech listing heads the fall pipeline. But Goldman Sachs warns the real supply test arrives in 2027.

Two-Front Supply Shock: Hormuz Blockade Bites as Black Sea Grain Corrupts

Brent is holding above $87 with the US declaring its Iran blockade "indefinite," while wheat futures jumped 3% after Ukraine knocked out two major Russian grain terminals. Energy and defense stocks are bid; equities are slipping. The question is whether these two supply disruptions converge into a single inflationary shock.

Energy Leads, Tech Cools: A Market Split Between Hormuz and Rate Relief

The S&P 500 steadies near records as oil surges on Strait of Hormuz escalation, semis take profit despite blowout earnings, and July's mild CPI takes a September rate hike off the table.

SpaceX Lockup Test Passed, But the Equity Supply Flood Is Just Beginning

SpaceX's first lockup expiry defied fears with a 35% surge, but the real test of equity supply-demand arrives Aug 20 and beyond — with biotech IPOs, PE secondaries, and Goldman's $1.3T buyback vs. $1.1T issuance framework setting the terms.

Hormuz at a Trickle, Russian Oil in the Crosshairs: Markets Bet on Calm the Tankers Contradict

Brent crude is up ~5% this week to ~$87 as Hormuz tanker traffic runs 90% below pre-war levels and the Senate's 100% tariff bill on Russian oil buyers heads to the House. The VIX sits at 15. The market is betting on calm the tankers contradict.

AI Earnings and Cooling CPI Push Stocks to Records — Oil Tests the Foundation

The Nasdaq's 1.2% rally is the cleanest read on the August tape: AI-infrastructure earnings are doing the heavy lifting, and soft July CPI cleared the Fed runway. But Brent crude at $88 on an indefinite Iran blockade is the risk the VIX is not pricing.

SpaceX Lockup Test Meets Biotech IPO Surge: A Market-Structure Checkpoint

SpaceX's first lockup tranche freed 911 million shares — more than its IPO float — and the stock rose. Biotechs raised $1.2B the same week. But the staggered unlock schedule means the real tests arrive Aug 20, September, and October.